Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Natixis Advisors LLC

Natixis Advisors LLC raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 24.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 63,651 shares of the medical equipment provider’s stock after buying an additional 12,602 shares during the period. Natixis Advisors LLC’s holdings in Zimmer Biomet were worth $6,871,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ZBH. Seven Eight Capital LP acquired a new position in Zimmer Biomet during the 1st quarter valued at about $296,000. Bessemer Group Inc. boosted its position in shares of Zimmer Biomet by 13.0% during the 1st quarter. Bessemer Group Inc. now owns 4,220 shares of the medical equipment provider’s stock valued at $557,000 after purchasing an additional 487 shares in the last quarter. Pitcairn Co. boosted its position in shares of Zimmer Biomet by 17.2% during the 1st quarter. Pitcairn Co. now owns 2,657 shares of the medical equipment provider’s stock valued at $351,000 after purchasing an additional 389 shares in the last quarter. Crewe Advisors LLC bought a new position in shares of Zimmer Biomet during the 1st quarter valued at about $31,000. Finally, EP Wealth Advisors LLC bought a new position in shares of Zimmer Biomet during the 1st quarter valued at about $282,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 0.8 %

Shares of Zimmer Biomet stock opened at $108.40 on Friday. The company’s fifty day simple moving average is $106.71 and its 200-day simple moving average is $109.85. The company has a market cap of $21.58 billion, a price-to-earnings ratio of 20.61, a PEG ratio of 2.04 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 1 year low of $101.47 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. Zimmer Biomet’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the company posted $1.65 earnings per share. As a group, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were paid a dividend of $0.24 per share. The ex-dividend date was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.89%. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Analyst Ratings Changes

Several research firms have recently weighed in on ZBH. Royal Bank of Canada raised their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, November 4th. Wells Fargo & Company raised their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Raymond James reduced their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Robert W. Baird reduced their price target on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Finally, Truist Financial raised their price objective on shares of Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a research report on Friday, November 1st. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $123.22.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.